Ketoconazole: Nursing Drug Guide, Hepatotoxicity & CYP3A4 Interactions
Healthcare medication guide: oral ketoconazole carries boxed warnings for fatal hepatotoxicity, QT prolongation with contraindicated co-medications, and adrenal suppression—reserved for systemic endemic mycoses when safer azoles cannot be used; topical and shampoo routes follow different labeling.
Oral tablets can cause fatal hepatotoxicity and are not indicated for nail, skin, or Candida infections. Use only for selected systemic endemic mycoses when safer azoles are unavailable. Monitor ALT weekly, take with food, avoid alcohol, and never give with contraindicated drugs such as simvastatin or oral triazolam.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Oral ketoconazole is a last-line systemic azole: verify indication is an approved endemic mycosis, obtain baseline and weekly ALT, take tablets with food, and stop therapy when ALT or symptoms cross labeling thresholds. Topical cream and shampoo are not substitutes for oral systemic therapy—and oral tablets must never be used for nail or routine skin candidiasis orders.
Most common brand names
Ketoconazole is available as oral tablets, topical cream, foam, and shampoo. Formulations are not interchangeable for indication or monitoring intensity.
Common brands include Nizoral (oral tablets and shampoo) and topical products such as Extina or Xolegel. Combination corticosteroid-antifungal products are different medications—verify the exact product on the label.
Why we give it — Indications
Indications and monitoring depend on route. Using oral tablets for superficial infections is an outdated, high-risk practice prohibited by current FDA labeling.
| Use | Detail |
|---|---|
| Systemic endemic mycoses (oral tablets only) | Blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis when other effective antifungal therapy is unavailable or not tolerated—not for fungal meningitis (poor CSF penetration). |
| Topical dermatologic and shampoo uses | Topical cream for tinea corporis, cruris, pedis, cutaneous candidiasis, seborrheic dermatitis, and tinea versicolor; shampoo for tinea versicolor per topical labeling—not for oral systemic replacement. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ketoconazole inhibits fungal cytochrome P-450–dependent lanosterol 14α-demethylase, depleting ergosterol and weakening the fungal cell membrane. Oral ketoconazole is also a potent inhibitor of human CYP3A4 and P-glycoprotein, which drives many serious drug interactions and QT-prolongation risk with co-medications.
Dosing overview
Dosing is route-specific. Oral therapy requires documented infection, baseline hepatic labs, and weekly ALT monitoring for the full course.
Missed dose: If a dose is missed, take when remembered unless near the next dose; do not double. For topical regimens, apply when remembered and continue per labeling duration for each infection type.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak (oral tablet) | ~3.5 mcg/mL within 1–2 h with a meal | Give oral tablets with food; absorption is reduced with achlorhydria or acid-suppressing medicines |
| Half-life (oral) | ~2 h early phase; ~8 h thereafter | Once-daily dosing still requires weekly hepatic monitoring—not “short half-life = low toxicity risk” |
| Systemic therapy duration | Usual course ~6 months until active infection subsides | Plan long-term ALT surveillance and interaction checks for the full course |
| Topical / shampoo | Local effect; systemic absorption minimal with appropriate use | Do not assume topical safety data replace oral boxed-warning monitoring when tablets are ordered |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm oral order is for an approved systemic endemic mycosis—not nail, skin, or mucosal candidiasis
- Review baseline ALT, AST, bilirubin, and symptoms; reconcile CYP3A4 and QT-prolonging drugs (statins, benzodiazepines, colchicine, etc.)
- Verify tablets will be given with a meal; note PPI/H2 blocker or antacid use that may reduce absorption
Contraindications
- Acute or chronic liver disease (oral tablets)
- Hypersensitivity to ketoconazole
- Concomitant contraindicated drugs (e.g., simvastatin, lovastatin, oral triazolam, methadone, cisapride, dofetilide, colchicine with renal/hepatic impairment—full list in labeling)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Simvastatin / lovastatin | Contraindicated—elevated statin levels and rhabdomyolysis risk | Hold statin; pharmacy must substitute or stop per prescriber; never administer together |
| Proton pump inhibitors / H2 blockers / antacids | Reduced ketoconazole absorption; subtherapeutic levels | Coordinate administration timing; acidic beverage may be needed with PPI per labeling—pharmacy-led plan |
| Colchicine, warfarin, cyclosporine, many CYP3A4 substrates | Elevated substrate levels; life-threatening toxicity reported with colchicine | Full MAR reconciliation; dose adjustments or alternative antifungal per prescriber and pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet with meal; topical thin film to affected skin; shampoo lathered on damp skin 5 minutes then rinsed
- Oral: swallow tablet whole with food; avoid alcohol per labeling
- Topical: apply to clean dry skin; avoid eyes; wash hands after application
- Shampoo: external use only; supportive care if accidental ingestion—do not induce emesis (aspiration risk)
Do not administer oral tablets for superficial fungal infections. Weekly ALT is mandatory during oral therapy. Stop therapy and obtain full hepatic panel when ALT exceeds ULN or 30% above baseline or when liver-injury symptoms appear.
Expected therapeutic response
- Clinical stabilization of systemic endemic mycosis on imaging/microbiology per prescriber plan
- ALT remains at or below monitoring thresholds with no hepatic symptoms
- Gradual improvement of topical fungal lesions over prescribed weeks (tinea pedis up to 6 weeks)
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Hepatotoxicity (oral tablets) | Serious—including fatal outcomes and transplantation | Monitor ALT weekly; hold and escalate when thresholds or symptoms occur; avoid other hepatotoxic drugs when possible |
| QT prolongation / arrhythmia risk | Serious with contraindicated co-medications | Screen MAR for dofetilide, quinidine, methadone, cisapride, and other contraindicated agents; teach palpitations/syncope reporting |
| Adrenal insufficiency | At doses ≥400 mg daily | Monitor patients with adrenal insufficiency or prolonged steroid use; report dizziness, weakness, nausea, vomiting |
| GI effects (nausea, vomiting, abdominal pain) | Common | Can overlap with liver injury—do not dismiss as “benign GI” without trending ALT |
| Rash, pruritus, anaphylaxis | Reported; anaphylaxis after first dose | Stop drug; urgent escalation for angioedema, pruritus with respiratory symptoms, or hypotension |
| Myopathy (with statins) | Serious with lovastatin/simvastatin | Never administer contraindicated statins; report muscle pain or weakness |
| Local irritation (topical/shampoo) | Common with topical products | Assess application site; discontinue if generalized rash or angioedema |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Acute oral overdose management in labeling is supportive and symptomatic. Activated charcoal may be considered within the first hour after ingestion. No specific antidote is listed in the reviewed prescribing information.
Nursing actions
- Stop further doses until prescriber, pharmacist, and local poison control or toxicology services advise per facility protocol
- Monitor hepatic panel, mental status, and cardiovascular status—severe hepatotoxicity has occurred at therapeutic and supratherapeutic exposures
- Accidental ingestion of topical shampoo: labeling advises supportive measures; do not induce emesis or gastric lavage due to aspiration risk (shampoo labeling)
Contact local poison control or medical toxicology services for guidance after large oral ingestion or serious symptoms. Use local emergency pathways for altered mental status, arrhythmia, or acute liver failure signs.
Look-alike / sound-alike and error prevention
- Nizoral oral tablets vs Nizoral shampoo vs ketoconazole cream—route and indication differ; oral tablets are not for nail or superficial dermatophyte infections per labeling
- Ketoconazole vs fluconazole vs itraconazole—different azoles, interaction profiles, and monitoring; verify prescriber intent on MAR
- Ketoconazole vs ketorolac—sound-alike high-risk confusion; independent double-check
- Topical ketoconazole vs oral ketoconazole—do not substitute topical products when systemic endemic mycosis therapy is ordered
- Reconcile acid-suppressing medicines and contraindicated CYP3A4 substrates at admission and transfer
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Oral administration | Give tablets with a meal; avoid alcohol; coordinate timing with PPIs/H2 blockers per pharmacy plan |
| Weekly ALT | Schedule and track weekly ALT for entire oral course—do not defer because patient “feels fine” |
| Topical cream | Thin film once daily (BID for seborrheic dermatitis per labeling); dermatologic use only—not oral mucosa |
| Shampoo | Apply to damp affected skin, lather, leave 5 minutes, rinse; external use only |
| Ask pharmacy when | Oral order for nail infection, new statin or QT-prolonging drug on MAR, or ALT above threshold |
On a small screen, swipe or scroll sideways to see the full table.
Red flags — Stop and act
Interrupt oral therapy and escalate when hepatic injury, arrhythmia symptoms, adrenal crisis signs, or anaphylaxis occur.
- Anorexia, nausea, vomiting, fatigue, abdominal pain, jaundice, dark urine, pale stools
- ALT above ULN or 30% above baseline on weekly monitoring
- Palpitations, syncope, or QT prolongation symptoms—especially with interacting antiarrhythmics or methadone
- Muscle pain or weakness with concurrent statin therapy
- Hypotension, angioedema, or bronchospasm after first dose (anaphylaxis reported)
High-risk populations
| Population | Considerations |
|---|---|
| Patients without obvious liver disease | Hepatotoxicity has occurred in patients without prior liver risk factors—never skip weekly ALT |
| Polypharmacy / ICU / transplant | High interaction burden with CYP3A4 substrates, immunosuppressants, and QT-prolonging drugs |
| PPI or H2 blocker use | Reduced absorption may lead to treatment failure—coordinate administration with pharmacy |
| Pregnancy | Animal teratogenicity at high doses; human data inadequate—use during pregnancy only if benefit justifies fetal risk per oral tablet labeling. |
| Lactation | Oral ketoconazole is excreted in milk; manufacturers recommend mothers not breastfeed during oral therapy. LactMed: topical shampoo/skin use poses little infant risk; avoid application to breast/nipple. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Weekly ALT (and baseline AST, bilirubin, alkaline phosphatase, INR per labeling) during entire oral course
- Signs of liver injury, adrenal insufficiency, and QT-related symptoms
- Therapeutic response of infection; topical site irritation
Document
- Formulation, dose, route, food intake with oral doses, and weekly ALT results
- Hold events, prescriber notification, and interaction reconciliation
- Patient teaching on alcohol avoidance and liver-injury symptoms
Patient teaching
- Take oral tablets with food; do not drink alcohol during therapy
- Report fatigue, nausea, abdominal pain, dark urine, yellow skin or eyes, or pale stools immediately
- Do not start or stop other medicines (including OTC and herbal) without prescriber/pharmacist review
- Topical and shampoo products are for external use only—different from oral tablets
- Complete prescribed topical duration (e.g., tinea pedis six weeks) even if skin looks better early
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- ALT above ULN or 30% above baseline—interrupt oral therapy per labeling
- Any sign or symptom suggesting liver injury
- Contraindicated interacting drug on MAR (e.g., simvastatin, oral triazolam, colchicine with renal/hepatic impairment)
- Acute or chronic liver disease—oral tablets contraindicated
- Oral order written for nail, dermatophyte, or candidiasis indication—clarify with pharmacy before giving
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Oral ketoconazole safety is a monitoring and interaction workflow—not a routine antifungal pill pass.
1. Check-before-you-give protocol
- Is this oral order for an approved systemic endemic mycosis with no safer azole available?
- Are baseline and weekly ALT scheduled and reviewed?
- Has pharmacy cleared contraindicated CYP3A4 and QT drugs on the MAR?
- Will the patient take the tablet with a meal and avoid alcohol?
2. High-alert and safety badge
Serious hepatotoxicity (oral)Oral ketoconazole has caused fatal hepatotoxicity and is not first-line for any fungal infection. Weekly ALT and interaction screening are mandatory when oral therapy is used.
3. Clinical workflow: hold and question rules
- Hold when weekly ALT crosses labeling threshold or hepatic symptoms appear
- Hold and clarify any superficial-infection oral order or contraindicated statin/benzodiazepine
- Involve pharmacy before restart after hepatotoxicity—rechallenge injury reported
4. Critical teach-back questions
- “How should you take the oral tablet?” With a meal, and I will report dark urine, yellow eyes, nausea, or abdominal pain right away.
- “Can this oral tablet treat my nail fungus?” Oral ketoconazole is not indicated for nail fungus per labeling—I should ask about safer antifungal options.
5. Care coordination
Pharmacist: Interaction review, ALT monitoring schedule, PPI/absorption plan, and alternative azole selection
Infectious diseases: Confirm endemic mycosis indication and transition to safer systemic azole when possible
🧠 Quick mental checklist
- Is oral ketoconazole truly the last-line choice for this infection?
- When is the next weekly ALT due—and what was baseline?
- Are contraindicated statins or sedatives still on the MAR?
- Will the dose be given with food without acid suppression interference?
- Does the patient know liver-injury red flags and to avoid alcohol?
Ketoconazole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ketoconazole using a tabbed inpatient case (MAR, labs, history, nursing notes) with oral therapy for systemic mycosis, weekly ALT trends, and CYP3A4 interaction risks—then work through priority action, cue recognition, trend interpretation, documentation cloze, ordered response, and matrix urgency sorting (recognise cues → analyse → prioritise → act → evaluate outcomes).
Select a tab to view MAR, labs, History, and nursing note details for this case.
- Ketoconazole tablet 200 mg PO daily — due 0800 with breakfast
- Omeprazole 20 mg PO daily — 0600 given
- Simvastatin 40 mg PO at bedtime — on MAR (filled last night)
- Ketoconazole 2% cream apply to feet BID — separate dermatology order
- ALT: 28 U/L (baseline, week 0) → 62 U/L (week 2) → 92 U/L (week 3, today)
- AST 45 U/L, total bilirubin 0.9 mg/dL — today
- Facility ALT upper limit of normal: 55 U/L
- Weekly ALT panel due per protocol; next not yet resulted
- 58-year-old with HIV (CD4 320), on stable ART
- Disseminated histoplasmosis; oral ketoconazole started after intolerance to preferred azole
- No history of chronic liver disease documented
- Reports fatigue and tea-colored urine × 2 days
- 0730: Patient ate 50% breakfast; asks if ketoconazole can be taken tonight instead
- 0745: Night nurse documented simvastatin given at 2200 despite pharmacy sticker “do not give with ketoconazole”
- 0800: Nurse preparing 0800 ketoconazole; notes weekly ALT now above ULN
Answer key & rationale
Frequently asked questions
Why is oral ketoconazole not used for skin, nail, or yeast infections?
FDA labeling states oral ketoconazole tablets are not indicated for onychomycosis, cutaneous dermatophyte infections, or Candida infections because serious hepatotoxicity risk outweighs benefit. Oral therapy is reserved for selected systemic endemic mycoses when other effective antifungals are unavailable or not tolerated.
How often should nurses monitor liver function during oral ketoconazole?
Obtain baseline hepatic labs before therapy. During treatment, serum ALT should be monitored weekly for the duration of oral therapy. Interrupt ketoconazole and obtain a full hepatic panel if ALT rises above the upper limit of normal or 30 percent above baseline, or if the patient develops liver-injury symptoms.
When should a nurse hold oral ketoconazole?
Hold and notify the prescriber when ALT exceeds the upper limit of normal or 30 percent above baseline, when liver-injury symptoms occur, when contraindicated interacting drugs are on the MAR, or when the patient has acute or chronic liver disease. Do not administer contraindicated drugs such as simvastatin, lovastatin, or colchicine in renal or hepatic impairment with ketoconazole.
Can ketoconazole shampoo or cream be used while breastfeeding?
LactMed notes topical shampoo or skin use poses little to no risk to the breastfed infant, but mothers taking oral ketoconazole should not breastfeed per manufacturer labeling. Avoid applying topical product to the breast or nipple area in nursing mothers.
What drugs must never be given with oral ketoconazole?
Labeling contraindicates many CYP3A4 substrates including simvastatin, lovastatin, colchicine in renal or hepatic impairment, oral midazolam, triazolam, alprazolam, methadone, cisapride, dofetilide, quinidine, and several others. Nurses must reconcile the MAR with pharmacy before each oral dose course.
References
-
U.S. National Library of Medicine. Ketoconazole tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc189ce2-3f10-260d-e053-2a95a90ae808
-
U.S. National Library of Medicine. Ketoconazole cream, 2% — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39b85d6a-9133-42e6-b7f8-58f045e9b9f0
-
U.S. National Library of Medicine. Ketoconazole shampoo, 2% — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c29d4ddc-aa1c-41c6-99ce-9aff35d213f6
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially
-
Drugs and Lactation Database (LactMed). Ketoconazole. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501228/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.